Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06931470 · ClinicalTrials.gov registry record · NA

A Pilot Feasibility and Acceptability Study of Remote ExerciSe Training mOdalities (PRESTO)

A NA study of Cardiovascular Diseases, sponsored by NYU Langone Health.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06931470: Recruiting NA study of Cardiovascular Diseases, sponsored by NYU Langone Health.

NCT06931470 is a NA study of Cardiovascular Diseases that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 30 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06931470, a NA study of Cardiovascular Diseases, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study will investigate the acceptability and efficacy of 12 weeks of: Smart-device app-based (MyZone) Asynchronous Virtual, Synchronous Virtual, and in-person aerobic training in individuals at risk for Cardiovascular Disease (CVD) who do are not meeting American Heart Association (AHA) guidelines for physical activity. The study aims to 1) Assess the effect of several approaches to remote aerobic training on measures of physical activity, cardiovascular fitness and CVD risk, and 2) Quantitatively and qualitatively evaluate exercise training program fidelity, implementation, effectiveness, and remaining barriers to acceptance. Participants will be asked to undergo Cardiopulmonary Exercise Testing (CPET) before and after 12-weeks of training via one of the 4 modalities (random assignment) listed above. They will respond to questions regarding acceptability of the interventions.

Primary Outcome

Outcome is measured via wearable technology (smart device).

Conditions Studied

Interventions

  • BEHAVIORAL In-person supervised exercise sessions
  • BEHAVIORAL Virtual classes (live-streamed sessions)
  • BEHAVIORAL Self-directed aerobic exercise
  • DEVICE Myzone mobile application
  • DEVICE Map My Fitness mobile application

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-04-06
Est. Completion 2027-12-01
Phase NA
NYU Langone Health

1,164 total trials

What NCT06931470 shows while recruiting

NCT06931470 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Cardiovascular Diseases appearing as the primary indexed condition, and to 5 interventions - of which In-person supervised exercise sessions is the first listed.

NCT06931470 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06931470 about?

NCT06931470 is a clinical study titled "A Pilot Feasibility and Acceptability Study of Remote ExerciSe Training mOdalities (PRESTO)". This study will investigate the acceptability and efficacy of 12 weeks of: Smart-device app-based (MyZone) Asynchronous Virtual, Synchronous Virtual, and in-person aerobic training in individuals at risk for Cardiovascular Disease (CVD) who do are not meeting American Heart Association (AHA) guideli...

What is the current status of trial NCT06931470?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-04-06. Estimated completion is 2027-12-01.

What conditions does trial NCT06931470 study?

This clinical trial studies the following conditions: Cardiovascular Diseases.

What interventions are being tested in trial NCT06931470?

The interventions under investigation include: In-person supervised exercise sessions (BEHAVIORAL), Virtual classes (live-streamed sessions) (BEHAVIORAL), Self-directed aerobic exercise (BEHAVIORAL), Myzone mobile application (DEVICE), Map My Fitness mobile application (DEVICE).

Who is sponsoring clinical trial NCT06931470?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06931470 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06931470's enrollment target sits among peer trials

30 262nd of 300 higher than 33 of 300 other Cardiovascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06931470, the US trial registry maintained by the National Library of Medicine. NCT06931470 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.